Optimization, Characterization and in vivo Evaluation of Paclitaxel-Loaded Folate-Conjugated Superparamagnetic Iron Oxide Nanoparticles

Gui, Gang; Fan, Ziqi; Ning, Yihuan; Yuan, Can‐Can; Zhang, Baolin; Xu, Qiang

doi:10.2147/ijn.s287434

Cited by 19 publications

(10 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the recent report [ 85 ], folic acid (FA) conjugated polyethylene glycol (PEG)/polyethyleneimine (PEI)-MNPs nanoparticles loaded with modified paclitaxel (SPTX) (SPTX@FA@PEG/PEI-MNPs) as a drug carrier with beneficial pharmacokinetics was proposed. Paclitaxel (PTX) has interesting anticancer activity, but it is insoluble in water.…”

Section: Intravenously Injected Mnpsmentioning

confidence: 99%

Pharmacokinetics of magnetic iron oxide nanoparticles for medical applications

Nowak-Jary

Machnicka

2022

J Nanobiotechnol

View full text Add to dashboard Cite

Magnetic iron oxide nanoparticles (MNPs) have been under intense investigation for at least the last five decades as they show enormous potential for many biomedical applications, such as biomolecule separation, MRI imaging and hyperthermia. Moreover, a large area of research on these nanostructures is concerned with their use as carriers of drugs, nucleic acids, peptides and other biologically active compounds, often leading to the development of targeted therapies. The uniqueness of MNPs is due to their nanometric size and unique magnetic properties. In addition, iron ions, which, along with oxygen, are a part of the MNPs, belong to the trace elements in the body. Therefore, after digesting MNPs in lysosomes, iron ions are incorporated into the natural circulation of this element in the body, which reduces the risk of excessive storage of nanoparticles. Still, one of the key issues for the therapeutic applications of magnetic nanoparticles is their pharmacokinetics which is reflected in the circulation time of MNPs in the bloodstream. These characteristics depend on many factors, such as the size and charge of MNPs, the nature of the polymers and any molecules attached to their surface, and other. Since the pharmacokinetics depends on the resultant of the physicochemical properties of nanoparticles, research should be carried out individually for all the nanostructures designed. Almost every year there are new reports on the results of studies on the pharmacokinetics of specific magnetic nanoparticles, thus it is very important to follow the achievements on this matter. This paper reviews the latest findings in this field. The mechanism of action of the mononuclear phagocytic system and the half-lives of a wide range of nanostructures are presented. Moreover, factors affecting clearance such as hydrodynamic and core size, core morphology and coatings molecules, surface charge and technical aspects have been described. Graphical Abstract

show abstract

Section: Intravenously Injected Mnpsmentioning

confidence: 99%

Pharmacokinetics of magnetic iron oxide nanoparticles for medical applications

Nowak-Jary

Machnicka

2022

J Nanobiotechnol

View full text Add to dashboard Cite

show abstract

“…Using the method reported by Gui et al [ 28 ], the standard curve of PTX was obtained using an ultraviolet (UV) spectrophotometer (Shimadzu UV 2600, Shimadzu Corporation, Kyoto, Japan). The nanoparticles were destroyed with an organic solvent (dimethyl sulfoxide: methanol = 1:1), and the concentration of PTX was determined and analyzed.…”

Section: Methodsmentioning

confidence: 99%

pH-Responsive Nanoparticles for Delivery of Paclitaxel to the Injury Site for Inhibiting Vascular Restenosis

et al. 2022

View full text Add to dashboard Cite

A high incidence of restenosis has been reported at the site of inflammation following angioplasty and stent implantation. The anti-proliferative drug paclitaxel (PTX) could help to reduce inflammation and restenosis; however, it has poor water solubility and serious adverse side effects at high doses. Given the presence of metabolic acidosis at the site of inflammation, we hypothesized that nanoparticles that are responsive to low pH could precisely release the loaded drug at the target site. We successfully constructed pH-responsive poly(D, L-lactic-co-glycolic acid) (PLGA) nanoparticles loaded with PTX and NaHCO3 as a pH-sensitive therapeutic agent (PTX-NaHCO3-PLGA NPs). The NPs exhibited remarkable pH sensitivity and a good safety profile both in vitro in rat vascular smooth muscle cells and in vivo in Sprague Dawley rats after tail vein injection. In the rat model, the PTX-NaHCO3-PLGA NPs treatment group showed suppressed intimal proliferation following balloon-induced carotid artery injury compared with that of the saline-treated control. Overall, these results demonstrate that our newly developed pH-responsive nanodrug delivery platform has the potential to effectively inhibit restenosis.

show abstract

“…Most anticancer drugs (e.g., doxorubicin, paclitaxel, curcumin, etc.) are administered intravenously, which often leads to a significant number of side effects [ 86 , 87 , 88 , 89 , 90 , 91 ]. The major limitation of present chemotherapeutic agents is the poor selectivity and the resultant toxicity [ 92 ].…”

Section: Synthetic Magnetic Nanoparticlesmentioning

confidence: 99%

Biosensors and Drug Delivery in Oncotheranostics Using Inorganic Synthetic and Biogenic Magnetic Nanoparticles

et al. 2022

View full text Add to dashboard Cite

Magnetic nanocarriers have attracted attention in translational oncology due to their ability to be employed both for tumor diagnostics and therapy. This review summarizes data on applications of synthetic and biogenic magnetic nanoparticles (MNPs) in oncological theranostics and related areas. The basics of both types of MNPs including synthesis approaches, structure, and physicochemical properties are discussed. The properties of synthetic MNPs and biogenic MNPs are compared with regard to their antitumor therapeutic efficiency, diagnostic potential, biocompatibility, and cellular toxicity. The comparative analysis demonstrates that both synthetic and biogenic MNPs could be efficiently used for cancer theranostics, including biosensorics and drug delivery. At the same time, reduced toxicity of biogenic particles was noted, which makes them advantageous for in vivo applications, such as drug delivery, or MRI imaging of tumors. Adaptability to surface modification based on natural biochemical processes is also noted, as well as good compatibility with tumor cells and proliferation in them. Advances in the bionanotechnology field should lead to the implementation of MNPs in clinical trials.

show abstract

Optimization, Characterization and in vivo Evaluation of Paclitaxel-Loaded Folate-Conjugated Superparamagnetic Iron Oxide Nanoparticles

Cited by 19 publications

References 35 publications

Pharmacokinetics of magnetic iron oxide nanoparticles for medical applications

Pharmacokinetics of magnetic iron oxide nanoparticles for medical applications

pH-Responsive Nanoparticles for Delivery of Paclitaxel to the Injury Site for Inhibiting Vascular Restenosis

Biosensors and Drug Delivery in Oncotheranostics Using Inorganic Synthetic and Biogenic Magnetic Nanoparticles

Contact Info

Product

Resources

About